Advertisement
Journal Home
Search for

Volume 11, Issue 2, Pages 57-63 (June 2009)


View previous. 4 of 6 View next.

Preoperative gabapentin in patients undergoing primary total knee arthroplasty

Cassie C. Dietrich, Michelle A. Kinney, Juan N. Pulido, Sheila L. Hoehn, Laurence C. Torsher, Edward D. Frie, James R. Hebl, Carlos B. MantillaCorresponding Author Informationemail address

Received 5 November 2008; received in revised form 9 February 2009; accepted 16 March 2009.

Summary 

Background

Patients undergoing total knee arthroplasty usually receive a multimodal analgesic regimen including peripheral nerve blockade, but may still experience significant pain. This study examined whether preoperative gabapentin decreases acute postoperative pain and opioid consumption in this setting.

Methods

Retrospective chart review of single institution, hospital-based orthopaedic practice. Consecutive patients undergoing unilateral elective primary knee arthroplasty were evaluated for perioperative gabapentin use. Sixty-one consecutive patients received gabapentin; for each, an age- and gender-matched control was identified.

Results

Patients in both groups demonstrated similar demographics, all received lumbar plexus blockade. Catheters were removed on postoperative day 2 (95%). There were no differences in postoperative pain scores or opioid use between groups. Overall, median verbal pain scores (IQR) were 0(1), 0(3), 1(3) and 3(3) in the post-anaesthesia care unit and postoperative days 0, 1 and 2, respectively. Postoperative consumption of other analgesics was not different across groups. Patients in the gabapentin group received a single-injection sciatic nerve block less often than patients in the control group (77% vs. 94%, respectively; p<0.05).

Conclusions

Patients undergoing unilateral total knee arthroplasty experience low pain scores utilizing a multimodal analgesic regimen including continuous lumbar plexus blockade independent of gabapentin use.

Department of Anesthesiology, Mayo Clinic, Rochester, MN, United States

Corresponding Author InformationCorresponding author at: Mayo Clinic, 200 First Street SW, Rochester, MN 55905, United States. Tel.: +1 507 255 7481; fax: +1 507 255 7300.

PII: S1366-0071(09)00005-9

doi:10.1016/j.acpain.2009.03.002


View previous. 4 of 6 View next.

Advertisement